Skaaltec

Skaaltec operates at the intersection of medical devices, neurotechnology, and neurorehabilitation. Its stated focus is post-stroke movement recovery in specialized rehabilitation clinics, with an integrated approach combining patient monitoring and non-invasive brain stimulation. SmartVNS is described as bringing sensing, algorithms, and AI together with neuromodulation, and the company emphasizes making rehabilitation more accessible through everyday activities. It would therefore be premature to claim a performance advantage over specific companies. Skaaltec appears to be an early-stage medical technology venture, with a team size listed in the 1–10 range and a funding history consisting of grants rather than disclosed equity rounds. Its selection for the Swiss National Medtech Team 2026 provides ecosystem recognition, but is not itself evidence of regulatory clearance or product-market traction. Further assessment of its competitive standing depends on product validation, regulatory progress, clinic adoption, and measurable patient outcomes.

Skaaltec’s recorded financing points to a grant-supported development path. InnoBooster provided a $173,759 grant dated Jul 14, 2023, followed by grants involving EPFL Innovation Park and Future of Health Grant totaling $11,375 on Feb 27, 2024, and a $3,538 DayOne accelerator grant on Aug 23, 2024. The stated aggregate funding is $188,672. This progression suggests continued early-stage support for product development rather than a disclosed transition to institutional equity financing. The 2026 selection for the Swiss National Medtech Team, announced on Jun 24, 2026, is a notable visibility and investor-access milestone, including participation in a Boston medtech investor roadshow. The company is listed in the 1–10 employee band. A meaningful next inflection point would be evidence of clinical validation, regulatory progress, or adoption by rehabilitation clinics; none of those outcomes is established by the information available here.